Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine- induced learning and memory impairment in rats

Masayuki Hiramatsu, Hiroyasu Murasawa, Toshitaka Nabeshima, Tsutomu Kameyama

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

The role of kappa opioid receptor agonists in learning and memory is controversial. In the present study, the effects of U-50,488H on scopolamine- , mecamylamine- and dizocilpine-induced learning and memory impairments in rats were investigated. Scopolamine (3.3 μmol/kg s.c.), a muscarinic cholinergic antagonist, and mecamylamine (40 μmol/kg s.c.), a nicotinic cholinergic antagonist, significantly impaired learning and memory in rats in a step-through type passive avoidance test. Administration of U-50,488H (0.17 or 0.51 μmol/kg s.c.) 25 min before the acquisition trial reversed the impairment of learning and memory induced by scopolamine and mecamylamine. Although low doses of scopolamine (0.17 μmol/kg) and mecamylamine (12 μmol/kg) had no effect, concurrent administration of both antagonists induced impairment of learning and memory. Scopolamine significantly increased acetylcholine release in the hippocampus as determined by in vivo brain microdialysis. On the other hand, mecamylamine significantly decreased acetylcholine release. U-50,488H completely blocked the decrease in acetylcholine release induced by mecamylamine, whereas it only partially blocked the increase of acetylcholine induced by scopolamine. On the other hand, an endogenous kappa opioid receptor agonist, dynorphin A (1-13), did not block the increase in acetylcholine release induced by scopolamine. The antagonistic effect of U-50,488H was abolished by pretreatment with nor- binaltorphimine (4.9 nmol/rat i.c.v.), a selective kappa opioid receptor antagonist. U-50,488H did not affect the impairment of learning and memory induced by the blockade of NMDA receptors by dizocilpine ((+)-MK-801). These results suggest that U-50,488H reverses the impairment of learning and memory induced by the blockade of cholinergic transmission and abolishes the decrease of acetylcholine release induced by mecamylamine via the kappa receptor-mediated opioid neuronal system.

Original languageEnglish
Pages (from-to)858-867
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume284
Issue number3
Publication statusPublished - 01-03-1998

Fingerprint

(trans)-Isomer 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide
Mecamylamine
Scopolamine Hydrobromide
Dizocilpine Maleate
Acetylcholine
Learning
kappa Opioid Receptor
Nicotinic Antagonists
Muscarinic Antagonists
Narcotic Antagonists
Microdialysis
Cholinergic Antagonists
N-Methyl-D-Aspartate Receptors
Cholinergic Agents
Hippocampus
Brain

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

@article{e2622656087442f995792653e28d12bb,
title = "Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine- induced learning and memory impairment in rats",
abstract = "The role of kappa opioid receptor agonists in learning and memory is controversial. In the present study, the effects of U-50,488H on scopolamine- , mecamylamine- and dizocilpine-induced learning and memory impairments in rats were investigated. Scopolamine (3.3 μmol/kg s.c.), a muscarinic cholinergic antagonist, and mecamylamine (40 μmol/kg s.c.), a nicotinic cholinergic antagonist, significantly impaired learning and memory in rats in a step-through type passive avoidance test. Administration of U-50,488H (0.17 or 0.51 μmol/kg s.c.) 25 min before the acquisition trial reversed the impairment of learning and memory induced by scopolamine and mecamylamine. Although low doses of scopolamine (0.17 μmol/kg) and mecamylamine (12 μmol/kg) had no effect, concurrent administration of both antagonists induced impairment of learning and memory. Scopolamine significantly increased acetylcholine release in the hippocampus as determined by in vivo brain microdialysis. On the other hand, mecamylamine significantly decreased acetylcholine release. U-50,488H completely blocked the decrease in acetylcholine release induced by mecamylamine, whereas it only partially blocked the increase of acetylcholine induced by scopolamine. On the other hand, an endogenous kappa opioid receptor agonist, dynorphin A (1-13), did not block the increase in acetylcholine release induced by scopolamine. The antagonistic effect of U-50,488H was abolished by pretreatment with nor- binaltorphimine (4.9 nmol/rat i.c.v.), a selective kappa opioid receptor antagonist. U-50,488H did not affect the impairment of learning and memory induced by the blockade of NMDA receptors by dizocilpine ((+)-MK-801). These results suggest that U-50,488H reverses the impairment of learning and memory induced by the blockade of cholinergic transmission and abolishes the decrease of acetylcholine release induced by mecamylamine via the kappa receptor-mediated opioid neuronal system.",
author = "Masayuki Hiramatsu and Hiroyasu Murasawa and Toshitaka Nabeshima and Tsutomu Kameyama",
year = "1998",
month = "3",
day = "1",
language = "English",
volume = "284",
pages = "858--867",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine- induced learning and memory impairment in rats. / Hiramatsu, Masayuki; Murasawa, Hiroyasu; Nabeshima, Toshitaka; Kameyama, Tsutomu.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 284, No. 3, 01.03.1998, p. 858-867.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine- induced learning and memory impairment in rats

AU - Hiramatsu, Masayuki

AU - Murasawa, Hiroyasu

AU - Nabeshima, Toshitaka

AU - Kameyama, Tsutomu

PY - 1998/3/1

Y1 - 1998/3/1

N2 - The role of kappa opioid receptor agonists in learning and memory is controversial. In the present study, the effects of U-50,488H on scopolamine- , mecamylamine- and dizocilpine-induced learning and memory impairments in rats were investigated. Scopolamine (3.3 μmol/kg s.c.), a muscarinic cholinergic antagonist, and mecamylamine (40 μmol/kg s.c.), a nicotinic cholinergic antagonist, significantly impaired learning and memory in rats in a step-through type passive avoidance test. Administration of U-50,488H (0.17 or 0.51 μmol/kg s.c.) 25 min before the acquisition trial reversed the impairment of learning and memory induced by scopolamine and mecamylamine. Although low doses of scopolamine (0.17 μmol/kg) and mecamylamine (12 μmol/kg) had no effect, concurrent administration of both antagonists induced impairment of learning and memory. Scopolamine significantly increased acetylcholine release in the hippocampus as determined by in vivo brain microdialysis. On the other hand, mecamylamine significantly decreased acetylcholine release. U-50,488H completely blocked the decrease in acetylcholine release induced by mecamylamine, whereas it only partially blocked the increase of acetylcholine induced by scopolamine. On the other hand, an endogenous kappa opioid receptor agonist, dynorphin A (1-13), did not block the increase in acetylcholine release induced by scopolamine. The antagonistic effect of U-50,488H was abolished by pretreatment with nor- binaltorphimine (4.9 nmol/rat i.c.v.), a selective kappa opioid receptor antagonist. U-50,488H did not affect the impairment of learning and memory induced by the blockade of NMDA receptors by dizocilpine ((+)-MK-801). These results suggest that U-50,488H reverses the impairment of learning and memory induced by the blockade of cholinergic transmission and abolishes the decrease of acetylcholine release induced by mecamylamine via the kappa receptor-mediated opioid neuronal system.

AB - The role of kappa opioid receptor agonists in learning and memory is controversial. In the present study, the effects of U-50,488H on scopolamine- , mecamylamine- and dizocilpine-induced learning and memory impairments in rats were investigated. Scopolamine (3.3 μmol/kg s.c.), a muscarinic cholinergic antagonist, and mecamylamine (40 μmol/kg s.c.), a nicotinic cholinergic antagonist, significantly impaired learning and memory in rats in a step-through type passive avoidance test. Administration of U-50,488H (0.17 or 0.51 μmol/kg s.c.) 25 min before the acquisition trial reversed the impairment of learning and memory induced by scopolamine and mecamylamine. Although low doses of scopolamine (0.17 μmol/kg) and mecamylamine (12 μmol/kg) had no effect, concurrent administration of both antagonists induced impairment of learning and memory. Scopolamine significantly increased acetylcholine release in the hippocampus as determined by in vivo brain microdialysis. On the other hand, mecamylamine significantly decreased acetylcholine release. U-50,488H completely blocked the decrease in acetylcholine release induced by mecamylamine, whereas it only partially blocked the increase of acetylcholine induced by scopolamine. On the other hand, an endogenous kappa opioid receptor agonist, dynorphin A (1-13), did not block the increase in acetylcholine release induced by scopolamine. The antagonistic effect of U-50,488H was abolished by pretreatment with nor- binaltorphimine (4.9 nmol/rat i.c.v.), a selective kappa opioid receptor antagonist. U-50,488H did not affect the impairment of learning and memory induced by the blockade of NMDA receptors by dizocilpine ((+)-MK-801). These results suggest that U-50,488H reverses the impairment of learning and memory induced by the blockade of cholinergic transmission and abolishes the decrease of acetylcholine release induced by mecamylamine via the kappa receptor-mediated opioid neuronal system.

UR - http://www.scopus.com/inward/record.url?scp=0031910789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031910789&partnerID=8YFLogxK

M3 - Article

C2 - 9495843

AN - SCOPUS:0031910789

VL - 284

SP - 858

EP - 867

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -